If Celgene Buys This Biotech, Investors Should Win Big-Time
Celgene (NASDAQ: CELG) has fallen on hard times of late -- or its stock has, at least. At the beginning of October, the biotech's share price was up 25% year to date. By the end of the month, Celgene stock was down more than 10% for the year.
The huge plunge stemmed from a couple of negative developments. First, Celgene announced disappointing results from a late-stage study of GED-0301 in treating Crohn's disease. Second, the company missed revenue expectations in the third quarter and lowered its full-year 2017 guidance, as well as its long-term outlook.
All of this bad news has some people questioning if Celgene should buy a biotech to improve its prospects. I think the answer is a definite "yes." In fact, if Celgene buys the right biotech, I believe that investors should win big-time.
Source: Fool.com
BioMarin Pharmaceutical Inc. Aktie
Überwältigende Zustimmung für BioMarin Pharmaceutical Inc. mit ausschließlich Buy-Einschätzungen.
Das Community-Kursziel von 102 € für BioMarin Pharmaceutical Inc. deutet auf eine deutliche Steigerung um mehr als 20% gegenüber dem aktuellen Kurs von 76.94 € hin.
